FDA Approves RSV Vaccine for Pregnant Women to Help Protect Newborns
Abrysvo indicated to be given between 32 and 36 weeks of pregnancy to prevent lower respiratory tract disease caused by RSV in infants from birth through 6 months
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.